Price Chart

DATE TIME TYPE PERIOD REPORTED
EPS
ESTIMATED
EPS
SURPRISE
02/03/2023* 01:00 EST Earnings Call Q4 2022 -- -- --
07/27/2022* -- Results Q2 2022 -- -- --
02/03/2022 -- Results Q4 2021 -- -- --
02/03/2022 01:00 EST Earnings Call Q4 2021 -- -- --
07/27/2021 -- Results Q2 2021 -- -- --
02/04/2021 -- Results Q4 2020 -- -- --
02/04/2021 08:00 EST Earnings Call Q4 2020 -- -- --
10/15/2020 -- Results Q3 2020 -- -- --
*Estimated Date/Time

Earnings

Next Report Date 07/27/2022 (est.)
EPS Estimate Upgrade
Last Actual EPS Upgrade
 
4.00
2.00
1.00
 
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
No data available
Last Report Date 02/03/2022
Beat/Miss Upgrade
Return Since -12.18%
Last FQE 12/31/2021
Next FQE 03/31/2022

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Feb. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 17, 2022

Dividends

Dividend Per Share (TTM) 9.992
2017
2018
2019
2020
2021
No data available
 
6.00%
4.00%
2.00%
 
Yield to Market 2.284
Yield to Sector 1.575
Yield to Industry 0.9011
Last Dividend Amt. 9.876
Dividend Frequency Annually
Last Ex-Dividend Date Mar. 17, 2022
Yield (TTM) 3.03%
Forward Yield 3.05%
Payout Ratio 56.10%
Cash Payout Ratio 47.68%
Consistent Payer (5Y) Yes
Consistent Growth (5Y) Yes

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Total Returns Comparison

Edit comparables

Annual Total Returns Versus Peers

Edit comparables
Loading chart...
Name
2015
2016
2017
2018
2019
2020
2021
YTD
4.33%
-14.16%
13.68%
-1.16%
34.57%
4.82%
23.40%
-17.62%
1.38%
11.96%
21.83%
-4.38%
31.49%
18.40%
28.71%
-17.67%
--
--
-1.39%
-26.17%
-9.84%
-39.32%
-4.26%
-36.36%
--
--
15.89%
21.68%
113.2%
151.4%
-50.51%
-25.65%
--
--
--
29.71%
-69.83%
-45.55%
-4.33%
-12.56%
--
--
--
--
--
--
-53.06%
-40.86%
As of May 20, 2022.

Profile

Edit
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's best-selling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
URL https://www.roche.com
Investor Relations URL https://www.roche.com/investors.htm
HQ State/Province N/A
Sector Healthcare
Industry Drug Manufacturers - General
Equity Style Large Cap/Blend
Next Earnings Release Jul. 27, 2022 (est.)
Last Earnings Release Feb. 03, 2022
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Mar. 17, 2022

Ownership

Insider Ownership Percentage Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Short Interest

Short Interest Upgrade
Percent of Shares Outstanding Short Upgrade
Jul '20
Nov '20
Mar '21
 
80.00%
40.00%
10.00%
 

Top Fund Holders

Symbol Dollars Invested % Weight
NBC4416 28.58M CHF 1.74%
CIEI.TO 208297.0 CHF 1.57%
FID1641 9.438M CHF 1.12%

Top Portfolio Holders

0 of 0

Other Resources

Whale Wisdom 13F Filings
Seeking Alpha Call Transcripts
Morningstar Insider Trading
Nasdaq Institutional Ownership